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ABCG2 is an efflux drug transporter that plays an important role in drug
resistance and drug disposition. In this study, the first three-dimensional
structure of human full-length ABCG2 analysed by electron crystallography
from two-dimensional crystals in the absence of nucleotides and transported
substrates is reported at 2 nm resolution. In this state, ABCG2 forms a
symmetric homodimer with a noncrystallographic twofold axis perpendicular to
the two-dimensional crystal plane, as confirmed by subtomogram averaging.
This configuration suggests an inward-facing configuration similar to murine
ABCB1, with the nucleotide-binding domains (NBDs) widely separated from
each other. In the three-dimensional map, densities representing the long
cytoplasmic extensions from the transmembrane domains that connect the
NBDs are clearly visible. The structural data have allowed the atomic model
of ABCG2 to be refined, in which the two arms of the V-shaped ABCG2
homodimeric complex are in a more closed and narrower conformation. The
structural data and the refined model of ABCG2 are compatible with the
biochemical analysis of the previously published mutagenesis studies, providing
novel insight into the structure and function of the transporter.
1. Introduction
The overexpression of several members of the ATP-binding
cassette (ABC) transporter superfamily is associated with
multidrug resistance (MDR) in cancer cells. These transpor-
ters extrude chemotherapeutics from the cell, reducing intra-
cellular drug concentrations (Deeley et al., 2006; Sarkadi et al.,
2006). The human breast cancer resistance protein (BCRP or
ABCG21) is one such ABC efflux drug transporter. ABCG2
is expressed in a wide range of solid, haematological and
lymphoid malignancies, and has been associated with MDR
and adverse disease outcomes in some of these tumours
(Natarajan et al., 2012; Robey et al., 2007). ABCG2 may play a
significant role in drug resistance in breast cancer. Multidrug-
resistant MCF-7 breast cancer cells generate extracellular
vesicles containing ABCG2, which can sequester anticancer
drugs, preventing them from reaching their intracellular
targets (Goler-Baron & Assaraf, 2011). Resistance to 5-fluoro-
uracil (5-FU) in a breast cancer patient population was also
found to be owing to ABCG2 overexpression (Yuan et al.,
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1 Abbreviations used: ABCG2, the second member of the G subfamily of the
ABC transporter superfamily; ABCB1, the first member of the B subfamily of
the ABC transporter superfamily or P-glycoprotein.
2009). A recent review also highlighted the importance of
ABCG2 in acute myeloid leukaemia (AML), affecting
response and survival rates (Xia & Smith, 2012).
ABCG2 is also highly expressed in organs important for the
absorption (the small intestine), elimination (the liver and
kidney) and distribution (for example, the blood–brain and
blood–placental barriers) of drugs (Maliepaard et al., 2001),
and has been recognized to be one of the key transporters
important for drug disposition and tissue protection (Giaco-
mini et al., 2010; Poguntke et al., 2010; Polgar et al., 2008). For
example, human subjects carrying the common variant Q141K
with reduced cell-surface expression and activity are at an
increased risk for altered pharmacokinetics of drugs such as
9-aminocamptothecin (Zamboni et al., 2006), irinotecan
(Zhou et al., 2005), rosuvastatin (Zhang et al., 2006) and
sulfasalazine (Urquhart et al., 2008). ABCG2 also eliminates
urate from the body, resulting in a higher risk of developing
gout in male patients harbouring Q141K owing to elevated
serum urate levels (Woodward et al., 2009).
Human ABCG2 is a glycosylated plasma-membrane
protein with a molecular weight of approximately 75 kDa.
Since its discovery in 1998, transport studies have shown that
ABCG2 possesses broad substrate specificity, ranging from
hydrophobic chemotherapeutics to hydrophilic organic anions
conjugated to sulfate, glutathione and glucuronate (Ni, Bikadi,
Rosenberg et al., 2010; Robey et al., 2009). It can also transport
nucleoside drugs and their monophosphate derivatives
(Fukuda & Schuetz, 2012). Most ABC transporters have a
topology with two transmembrane domains (TMDs) and two
nucleotide-binding domains (NBDs), in which each TMD is
N-terminal to a cognate NBD (Hyde et al., 1990). Members
of the G subfamily of ABC transporters such as ABCG2,
however, show the reverse topology, with the NBD being
N-terminal to the cognate TMD (Ni, Bikadi, Rosenberg et al.,
2010; Polgar et al., 2008). ABCG2 is also unique in that it
consists of only one NBD and one TMD fused together, and
hence it must dimerize in order to form a functional trans-
porter (Dezi et al., 2010; Xu et al., 2004). Previous mutagenesis
studies have identified several residues in the TMD of
ABCG2, including Arg482 and Pro485 in the third TM -helix
(TM3), that are important determinants of substrate specifi-
city and/or overall transport activity (Honjo et al., 2001; Ni,
Bikadi, Cai et al., 2010; Ni et al., 2011; O¨zvegy-Laczka et al.,
2005). The mechanism by which ABCG2 transports drugs is
still poorly understood at the molecular level. As proposed in
the ATP-switch and constant-contact models (George & Jones,
2012; Linton & Higgins, 2007), an ABC transporter undergoes
several major conformational changes that drive the transport
of substances across the membrane. The open apo inward-
facing and the outward-facing conformations have been
demonstrated for the Escherichia coli ABC lipid transporter
MsbA in a lipid environment using double electron-electron
resonance spectroscopy (Zou et al., 2009), which supports the
ATP-switch model. However, other studies seem to support
the constant-contact model, in which the NBDs are proposed
to maintain contact in the drug-transport cycle (Jones &
George, 2009).
In eukaryotic ABC transporters and one class of prokar-
yotic ABC transporters, there is a growing body of evidence
that coupling of ATP binding/hydrolysis at the NBDs to TMD
movement is mediated via two intracellular loops (ICLs)
formed by long extensions of the TM -helices (Kerr et al.,
2010). One of the ICLs crosses over from the opposing TMD
so that a hinge-like movement of the two TMDs can be
coupled to closure of the NBD–NBD interface and occlusion
of ATP. In the G subfamily of ABC transporters, predictions
based purely on hydrophobicity variation in the primary
structure suggest that the ICLs are of differing lengths and are
relatively short [for example, 28 and eight residues for the first
(between TM2 and TM3) and the second (between TM4 and
TM5) ICLs, respectively, in ABCG2 (Hazai & Bika´di, 2008; Li
et al., 2007)] compared with the ICLs found in other ABC
transporter families (for example, 49–60 residues for all four
ICLs in ABCB1; Kos & Ford, 2009). These differences suggest
that there is no cross-over of an ICL from one ABCG
monomer to the opposing NBD, or at least that such a cross-
over must be organized differently to the situation in other
eukaryotic ABC transporter families. However, our recent
mutagenesis and antibody labelling data on ABCG2 conflict
with the computer-predicted model, revealing a long (40
residues) ICL2 connecting TM4 and TM5. This arrangement
would be much more compatible with the classical model for
ABC exporter structure and function (Rosenberg et al., 2010;
Wang et al., 2008). Clearly, three-dimensional structural data
for the ABCG subfamily are necessary to resolve these
questions. In the present study, we have determined the three-
dimensional structure of ABCG2 by cryo-electron microscopy
(cryo-EM) of two-dimensional crystals grown in the absence
of nucleotides and transported substrates. Here, we describe
the structure of ABCG2 at 2.0 nm resolution. This study is
based upon the two-dimensional crystallization studies of full-
length ABCG2 that we have previously reported (Rosenberg
et al., 2010). Although the structural data only relate to one
conformational state, the resolution of the data is sufficient to
identify the NBD and the TMD components of ABCG2 and
their organization in the homodimeric complex. The NBDs of
ABCG2 were separated and the TMDs showed a V-shaped
conformation. This allowed the refinement of the homology-
based structural model of ABCG2 that we previously devel-
oped, which should offer further insights into its mechanism of
action.
2. Materials and methods
2.1. Expression, purification and crystallization
ABCG2 was expressed in the yeast Pichia pastoris and
purified using a polyhistidine tag in the presence ofN-dodecyl-
-d-maltoside. These procedures and the formation of two-
dimensional crystals have been described previously (Rosen-
berg et al., 2010).
2.2. Image acquisition and processing
Images were collected on FEI G2 Polara and Tecnai F20
field-emission microscopes operated at 300 and 200 kV,
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respectively. The specimen was maintained at <100 K
throughout. Primary magnifications of 50 000–80 000 were
used with a mean underfocus ranging from 200 to 1500 nm.
Images were recorded in low-dose mode with total dose of 10–
12 e A˚2. The crystals were imaged at tilt angles in the range
0–60 in order to obtain three-dimensional data. Images were
recorded on a 4000  4000 pixel CCD camera and, for some
data, on Kodak SO-163 film, which was developed for 12 min
in full-strength Kodak D19 developer and then scanned as
described previously (Rosenberg et al., 2010).
Images were processed using the 2dx software package
(Gipson et al., 2007), which uses theMRC software (Crowther
et al., 1996) to correct for lattice distortions and the effect of
the contrast-transfer function before extracting structure
factors from the crystal images. To prevent reference bias in
the unbending routine, we used high signal-to-noise references
(with IQ values of 2 and 3, where 1 is the highest signal to
noise). Initial estimates of tilt angles were calculated from the
lattice parameters using the EMTILT program (Amos et al.,
1982), and crystal data were processed using the p121 plane-
group symmetry as described previously (Rosenberg et al.,
2010). The three-dimensional data set was merged using the
same symmetry using the 2dx_merge component of the soft-
ware package. The final three-dimensional map was calculated
using CCP4 routines (Winn et al., 2011) with a negative B
factor of 150 A˚2. The maps were examined using the
Chimera package (http://www.cgl.ucsf.edu/chimera; Pettersen
et al., 2004) and real-space averaging of the two ABCG2
monomers in the homodimer.
2.3. Electron tomography
Tomographic tilt series were recorded using an FEI G2
Polara transmission electron microscope operated at 300 kV.
Tomography data were recorded using the FEI Tomography
control software, with tilting between 65 and +65 with 2.5
increments up to +50 and then 1 increments up to 65, as
described previously (Rosenberg et al., 2011). The total elec-
tron dose was restricted to 40 e A˚2. Subsequent processing
was carried out with the IMOD tomography package as
described previously (Kremer et al., 1996). No fiducial gold
markers were used. Therefore, tilted images were initially
aligned using a patch-tracking algorithm similar to the
approach used by Castan˜o-Dı´ez et al. (2010), which tracks
structural features through the tilt images. After editing, the
mean residuals for the patches were <3 pixels using 2048 
2048 images at 0.3 nm per pixel.
2.4. Subtomogram averaging
To generate a three-dimensional map independent of
electron crystallography, a subtomogram average was gener-
ated using the two-dimensional crystal unit cell as input by
aligning subvolumes of ABCG2 using the Dynamo (Castan˜o-
Dı´ez et al., 2012) and EMAN2 (Tang et al., 2007) software with
the preliminary average as a reference. Subtomogram aver-
aging is not usually performed on two-dimensional crystals,
but since the sample is crystalline the rotation of the particles
is more limited, thus reducing the degrees of freedom of
movement of the subvolumes, which may enhance the reso-
lution of the final three-dimensional map. The resulting
subtomogram average was generated from 100 subvolumes
and the final volume was twofold-averaged using Chimera
(Pettersen et al., 2004). Fourier shell correlation was used to
ascertain the resolution from two independently determined
subtomogram averages (Saxton & Baumeister, 1982). To
determine whether our map is consistent with the results from
high-resolution X-ray crystallography of ABC transporters,
the X-ray structure of murine ABCB1 (PDB entry 4ksb; Ward
et al., 2013) was placed into the subtomogram average by
manual fitting and by automatic fitting using the Chimera
command ‘fit in map’ (Pettersen et al., 2004).
2.5. Molecular modelling
The original closed apo model of ABCG2 which we
previously developed using the mouse ABCB1 structure as a
template (PDB entry 3g60; Rosenberg et al., 2010) was used
for model refinement based on the three-dimensional ABCG2
map of this study. The Situs software package (Wriggers, 2010)
was used to align the original model with the ABCG2 map as
follows. Visual inspection of the structural alignment implied
significant differences between the ABCG2 map and the
model, namely because of the spatial arrangement of the two
monomers. Therefore, the new model was optimized by
cutting the model into two symmetric halves, and the two
halves were aligned individually. The resulting aligned halves
were used as a template for modelling, resulting in a more
closed form. Homology modelling of ABCG2 based on this
artificial template was carried out using theMODELLER9.11
package (Sˇali & Blundell, 1993). A bundle of ten models from
random generation of the starting structure were calculated
using the very thorough molecular-dynamics model-optimi-
zation option in the MODELLER package. The best model
was selected based on the DOPE score, aMODELLER score
function reflecting model quality. Finally, the resulting
homodimeric model of ABCG2 was structurally aligned using
chains as rigid bodies by the Situs software package. The
quality of the final model was evaluated using PROCHECK
(Laskowski et al., 1993). The percentage of residues that were
found in the allowed regions of the Ramachandran diagram
was 99.1%. The value of the G-factor of the final open apo
ABCG2 model was 0.2, which is an indication of good
quality.
2.6. Accession codes
The three-dimensional map of ABCG2 has been deposited
in the EMDB with accession code EMD-2715.
3. Results
3.1. Two-dimensional crystal formation
For this study, ABCG2 was overexpressed in P. pastoris and
purified with N-dodecyl--d-maltoside, and two-dimensional
crystals were grown as described previously (Rosenberg et al.,
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2010). We did not reconstitute ABCG2 into a lipid bilayer, as
commonly undertaken in electron crystallography. Instead, we
followed an adaptation of a three-dimensional crystallization
protocol without the addition of lipids, in which the two-
dimensional crystals were grown on the surface of transmis-
sion electron microscope (TEM) grids. This methodology
has been successfully used for crystallizing other membrane
proteins such as H+-ATPase (Auer et al., 1999).
3.2. Plane group, crystal packing and resolution assessment
TEM images showed large two-dimensional crystalline
arrays of ABCG2 (Fig. 1). Electron tomography was used to
measure the thickness and the basic organization such as
the crystal packing of the two-dimensional crystals, which
confirmed that they were single-layered (Fig. 2a). The screw
axis places two ABCG2 molecules in opposite orientations
relative to the crystal plane (Rosenberg et al., 2010). The
statistics for these crystals shown in Table 1 indicate that the
resolution of the crystals extends to 2.0 nm. The unit-cell
parameters for this batch of crystals were a = 6.98 nm,
b = 12.25 nm,  = 89.9. These dimensions are larger than
those we reported previously (Rosenberg et al., 2010), which
were a = 5.73 nm, b = 8.8 nm,  = 89.7, although the two-
dimensional plane group is the same. The projection maps also
appeared to be different (Fig. 3). This could be because the
ABCG2 in the crystals in this study is in a different confor-
mation. Recently, the crystal structures of three inward-facing
conformations of mouse ABCB1 derived from two different
crystal forms have been described (Ward et al., 2013). These
authors suggested that changes in the growth conditions could
account for the differences in unit-cell parameters, which were
considerable. Therefore, a conformational change accom-
panied by changes in crystal-growth conditions could account
for the differences in unit-cell parameters observed in this
study. Recently, various conformations of ABCB10 have also
been shown in the absence of and in complex with different
nucleotide analogues (Shintre et al., 2013). Moreover, for an
unpublished ABCG2 crystal form in the presence of a drug,
which had a smaller unit cell, we were able to fit the structures
of Sav1866 (PDB entry 2hyd; Dawson & Locher, 2006) and
MsbA (PDB entry 3b5y; Ward et al., 2007) into the three-
dimensional map (data not shown).
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Figure 1
Electron-microscopic characterization of two-dimensional crystals of ABCG2. (a) Negative-stain electron-microscopic image of two-dimensional
crystals of ABCG2 with 2%(w/v) uranyl acetate. The scale bar represents 35 nm. (b) A respective power spectrum. (c) An overview of the crystal at
lower magnification, where the arrows show where the crystal originates. The scale bar represents 500 nm.
Table 1
Data-analysis summary (projection and three-dimensional reconstruc-
tion).
Crystal plane-group symmetry p121
Crystal unit-cell parameters
a, b, c (nm) 6.98  1.3 (n = 5), 12.25  0.31 (n = 5), 20
 () 89.9  0.4 (n = 5)
Projection data for resolution range 100–2.0 nm.
IQ = 1 IQ = 2 IQ = 3 IQ = 4 IQ = 5 All IQs
Phase residual () 27.6 35.6 39.7 53.7 12.7 31.0
No. of comparisons 12 11 7 9 15
Three-dimensional data.
No. of images 76
Range of defocus (mm) 0.2–1.5
IQ range used 1–7
Tilt range used () 0–60
Total No. of measurements 3251
Total No. of fitted unique reflections 1752
Overall weighted phase residual () 27.4
Completeness to 1.6 nm with 60 tilt (%) 76
Effective resolution cutoffs (nm) 2.0 (in-plane), 2.0 (vertical)
Statistics of the processing and
merging of the crystallographic data
from 76 images of two-dimensional
crystals tilted up to 60 are given in
Table 1. The good processing statistics
(an overall weighted phase residual of
27.4 for a merged data set) suggests
that we are dealing with well ordered
two-dimensional crystals. No reference
bias was used in the unbending routine
since references with IQ 2 and IQ 3,
which have high signal-to-noise ratios,
were used (2dx Basel Workshop 2012,
personal communication). Supplemen-
tary Fig. S1 shows examples of the
computed Fourier transforms from
images of exemplar crystals tilted to 0,
45 and 60 (from left to right). Lattice
lines were fitted with smooth curves (see
Supplementary Fig. S2) and sampled to
generate a set of structure factors from
which a reproducible three-dimensional
map of ABCG2 was calculated. These
low-resolution lattice lines display less
deviation from the fitted curve for the
phase component (upper panels) versus
the amplitude component, which is
typical for electron crystallography-
derived data (Ford & Holzenburg,
2008). The absence of data owing to the
so-called missing cone (tilting limit of 60) and undersampling
of data along the c direction means that the average resolution
of the three-dimensional map will probably be close to the
2.0 nm resolution cutoff employed for the sampling of lattice
lines along the c direction. The final three-dimensional map
(Fig. 4) was generated with a negative temperature factor of
150 A˚2, which is a suitable value for a map of 2.0 nm reso-
lution along the a axis and 2.0 nm resolution along the c
direction.
3.3. Description of the three-dimensional map
The analysis of two-dimensional crystals described above
generated a clearly interpretable three-dimensional map,
which allows the delineation of boundaries for the molecules
(Fig. 4). The ABCG2 homodimer and the tomogram (see
below) have a maximal total thickness of about 13 nm
(Fig. 2a). The tomogram also showed that the two-dimensional
crystals were single-layered crystals and displayed p121
symmetry because of the ‘up/down’ configuration of the
molecules (Fig. 2a). In Fig. 4, which is viewed along the c axis,
the high-density central regions of the map have a distinctive
chevron or V shape subtending an angle of about 60 with
each arm of the V, which is about 13 nm long and 11 nm across.
These dimensions are similar to other homologous ABC
transporters in the PDB. The V-shaped density is flanked at
the upper and lower surfaces of the map by more globular
densities of about 4.6 nm across and about 3.0 nm in depth.
The V-shaped densities in the two crystallographic symmetries
have a local noncrystallographic twofold (C2) symmetry axis
(see also the dashed line in Fig. 5a) and related halves of the
unit cells are tightly packed next to each other in the map.
Intercalation between V-shaped densities in adjacent unit cells
along the c axis is significant, giving a tight packing of mole-
cules in the crystal.
The V-shaped molecules are standing up on their two open
ends, with the next molecule hanging upside down with the
open ends at the top. This is different from a previous inter-
pretation that we calculated from a different batch of two-
dimensional crystals, in which the V-shaped ABCG2 mole-
cules were interpreted as lying horizontally in the two-
dimensional crystal plane, so that the two open ends of the
V-shaped molecules were at the top and bottom of the two-
dimensional crystal layer (data not shown). This could be
because in the study described in this manuscript we used a
new batch of two-dimensional crystals. The earlier structure
was much noisier, as supported by the statistics, which had an
overall weighted phase residual of 47, whereas in this study
the overall weighted phase residual was 27.4 (a value of 90
corresponds to random data). The lattice dimensions in the
earlier study were 5.8  8.8 nm, whereas in this manuscript
they were 6.98  12.25 nm, also suggesting that the crystal
packing might be different. This finding suggests that ABCG2
can exhibit alternate crystal packings, which may be related to
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Figure 2
Tomographic characterization of two-dimensional crystals of ABCG2. (a) Three-dimensional
tomographic volumes of ABCG2. A slice perpendicular to the crystal plane and along one crystal
axis taken from an electron-tomographic reconstruction of the two-dimensional crystal zone is
shown. This represents an unfiltered three-dimensional isosurface, which shows a single-layered,
approximately 13 nm thick profile. (b) Subtomogram average side view of the ABCG2 homodimer.
Two ABCG2 monomers form a V-shaped dimer with an angle of approximately 60 between their
long axes. Threshold levels are 1.5 (mesh) and 2 (light grey). The map was fitted with an atomic
model of murine ABCB1 (PDB entry 4ksb). The scale bar represents 2.0 nm.
ABCG2 exhibiting different conformational states (Rosen-
berg et al., 2010).
The most immediate interpretation of the density in the
map is that the ABCG2 homodimer is in an inward-facing
conformation with the V shape formed by the TMDs and the
flanking globular domains being the NBDs. In this config-
uration, the crystal will have the more polar domains on each
surface, whilst the more hydrophobic TMDs will be sand-
wiched in the centre of the crystal.
3.4. Interpretation of the three-dimensional map
We used the murine ABCB1 coordinates (main-chain
atoms) with an inward-facing conformation (PDB entry 4ksb;
Ward et al., 2013) and fitted them to the homodimer density in
the three-dimensional map of ABCG2 using the Chimera ‘fit
to map’ function, as illustrated by the red tracings in Fig. 4.
This ABCB1 structure was chosen because it was in an inward-
facing state with the V shape constituting the angle, which
appears to be more compatible with the three-dimensional
map compared with other ABC transporter structures (see
below). The fit was reasonable, with a correlation coefficient of
0.75 when a map for the fitted model (with a resolution cutoff
of 2.0 nm) was compared with the experimental map. The
average map value per atom for fitted main-chain ABCB1 was
about 2.1 above the mean density. Murine ABCB1 gave the
best fit to this map, but the correlation coefficient suggests that
there may be differences in the maps because the red chain
traces do not entirely echo the EM-derived contours. This may
reflect the fact that ABCG2 is radically different from existing
ABC transporters because of the reverse topology present
in this membrane protein, in which the nucleotide-binding
domain (NBD) is N-terminal to the TMD, whereas the
opposite is true for other ABC transporter subfamilies. Some
densities that were not accounted for could be regions in
ABCG2 that are not present in ABCB1 and seem to aid in
crystalline packing. To confirm the orientation of the three-
dimensional map, we used the Phyre2 server (Kelley &
Sternberg, 2009) based on alignment with chain B of the
murine ABCB1 structure (PDB entry 3g5u; Aller et al., 2009)
to predict a protein structure for the NBD globular domain of
ABCG2. This was successfully achieved with 100% confidence
in the model. The predicted NBD structure was used to
interrogate the three-dimensional map and docked with a
correlation coefficient of 0.8 at the putative NBD site of the
map, whereas the correlation coefficient was poorer when the
predicted NBD structure was docked in other regions of the
map. We also tried to fit the outward-facing Sav1866 structure
(PDB entry 2hyd; Dawson & Locher, 2006) into the ABCG2
map. The fit was worse than that for the ABCB1 structure
(PDB entry 4ksb), with a correlation coefficient of about 0.34
and an average map value per atom of 1.3 and with more
clashes between unit cells (Supplementary Fig. S3a). The
MsbA structure (PDB entry 3b5w; Ward et al., 2007), a wide-
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Figure 3
The p121-symmetrized projection map of two-dimensional crystals of
ABCG2 in the absence of nucleotides and transported substrates. The
map was calculated from merged amplitudes and phases from five
independent lattices of crystals embedded in vitreous ice. Densities above
the mean and negative densities are shown by continuous and dotted
lines, respectively. This represents a top view of the two-dimensional
crystal along the z axis. The rectangular unit cell (6.98  12.25 nm) and
the screw axes for plane group p121 have been drawn in. The
approximate centre of the noncrystallographic twofold symmetry axis is
indicated by an asterisk. The scale bar represents 2.0 nm.
Figure 4
Alignment of the murine ABCB1 structure (PDB entry 4ksb) with the
ABCG2 map. The densities within the ABCG2 map (grey surface) and
interpretation of the packing of the molecules using the mouse ABCB1
structure (red chain traces) as a guide are shown. The isocontour level is
1.7. This is from the side of the two-dimensional crystals along the a axis;
the vertical height of the two-dimensional crystal is approximately 20 nm,
with an individual molecule having a height of approximately 13 nm. The
scale bar represents 2.4 nm.
open apo inward-facing conformation, was fitted into the
ABCG2 map with a correlation coefficient of 0.42 and an
average map value per atom of 0.90 (Supplementary
Fig. S3b). The murine ABCB1 structure (PDB entry 3g60;
Aller et al., 2009), a closed apo inward-facing conformation,
fitted better, with a correlation coefficient of 0.47 and an
average map value per atom of 1.0 (Supplementary Fig. S3c).
We tried another inward-facing ABCB10 structure (PDB
entry 3zdq; Shintre et al., 2013), which was also fitted with a
reasonable correlation of 0.53 and an average map value per
atom of 0.84 above the mean density complemented by
the additional symmetry of ABCB10 (Supplementary
Fig. S3d).
3.5. Noncrystallographic symmetry averaging
Noncrystallographic symmetry averaging was applied to the
final density map using the fitted ABCB1 model (PDB entry
4ksb) as a guide to identify the local noncrystallographic
twofold symmetry axis. Density within 2.0 nm of the fitted
model was extracted and then averaged with a version of the
map rotated by 180 around the local C2 symmetry axis
(Figs. 5a and 5b). The correlation between the unrotated and
rotated versions of the map was 0.7, which is likely to be a
reflection of the lack of noise in the map and little deviation
from twofold symmetry, and may confirm the presence of a
noncrystallographic twofold axis perpendicular to the crystal
plane. Although the ABCB1 structure (PDB entry 4ksb) is not
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Figure 5
Views of the ABCG2 dimer and an ABCG2 monomer after symmetry averaging from the electron-crystallographic data. The symmetrized map (semi-
transparent grey surface) and the fitted mouse ABCB1 structure (PDB entry 4ksb; red chain trace) is shown in (a) as the front view, with the dotted lines
showing the C2 symmetry axis. (b) Side view of the ABCG2 dimer. (c) View of an ABCG2 monomer from the twofold rotational symmetry axis looking
outwards at a 2.0 nm thick slice. (d) View of the NBDs of an ABCG2 homodimer. The overall arrangement of the major domains between the ABCG2
map and the ABCB1 structure appears to be similar. The NBDs in (a) and (b) are indicated by black filled arrows. Additional densities in (a) and (b)
(indicated by open arrows) are observed in the ‘beak’ regions between the TMD and the NBD as well as in the NBD regions close to the position of
C-terminus of ABCB1. The TMD, ICL and NBD regions in (c) and (d) are also depicted. The isocontour level is 1.7. (e) shows a projection map of the
three-dimensional volume from above down onto the membrane plane by calculating a single slice through the volume using the map-generation
program (FFT) in CCP4 in the z direction. Negative contour values were omitted for clarity. The scale bar in (e) is the same as that in (c).
symmetric, visual inspection with Chimera revealed that it was
reasonably close to C2 symmetry, and the correlation coeffi-
cient was slightly higher for ABCB1 (PDB entry 4ksb) than
for ABCB10 (PDB entry 3zdq) for the three-dimensional
map fit.
3.6. ABCG2 structure
The NBDs in the final symmetry-averaged map show a
reasonably close correspondence in terms of shape to the
expected NBD envelope and fold (Fig. 5). From sequence
alignment of ABCG2 versus known NBD structures, the
expected C-terminal end of the NBD lies at the bottom of the
domain (Fig. 5a, black filled arrows). As indicated, there are
additional densities near the boundaries between the NBDs
and TMDs (Fig. 5a, open arrows) and in the NBDs close to the
expected C-terminal region of the fitted NBD in the ABCG2
map (Fig. 5b, open arrows). As well as helping to form crys-
talline contacts, they may be part of the sequence that is
unique to ABCG2 (see below). Fig. 5(c) shows the three-
dimensional map of one ABCG2 monomer after symmetry
averaging, which indicates the approximate locations of the
NBD, TMD or ICL regions in an ABCG2 monomer. Notably,
densities representing the long cytoplasmic extensions from
the TMDs that connect the NBDs are clearly visible (Fig. 5a,
the regions sandwiched between the open and black filled
arrows), and these cytoplasmic extensions are likely to be the
ICL regions. This appears to have a much rougher surface
rendering, which suggests undersampling, giving the impres-
sion that these data do not correlate with the projection map
characterized by smooth contours in Fig. 3. To allay this
concern, we determined a projection of the three-dimensional
volume from above down onto the membrane plane (Fig. 5e).
Fig. 5(e) shows a close correlation of one ABCG2 monomer
with the projection map in Fig. 3, reinforcing the information
obtained. Moreover, we used SPIDER (Frank et al., 1996) to
project the volume shown in Fig. 5(c) in the Z direction over
relevant slices. Reassuringly, this gave an equivalent map to
Fig. 5(e) (data not shown). Fig. 5(d) shows the NBDs of an
ABCG2 homodimer.
3.7. Subtomogram averaging
To confirm the three-dimensional map, an independent
method of subtomogram averaging was used to generate a
subtomogram average with Dynamo (Castan˜o-Dı´ez et al.,
2012) and EMAN2 (Tang et al., 2007) (Fig. 2b). Both methods
produced similar maps and the findings presented here are
from Dynamo. Fourier shell correlation indicated a resolution
of 4.0 nm at 50% correlation (data not shown). The sub-
tomogram average displayed a V-shaped three-dimensional
map exhibiting twofold symmetry, with an angle of approxi-
mately 60 between the two monomers, similar to that
described by electron crystallography. The X-ray structure of
murine ABCB1 (PDB entry 4ksb; Ward et al., 2013) fitted the
main globular density with a high correlation of 0.8 at 40 A˚,
suggesting that ABCB1 fitted into this 40 A˚ map, whilst the
NBDs and TMDs are just resolved (Fig. 2b). The dimer
interface appears to be perpendicular to the crystal plane,
which in this case corresponds to the expected membrane
plane.
3.8. Molecular modelling
We have previously developed homology models of
ABCG2 based upon the membrane topology that we deter-
mined experimentally (Ni, Bikadi, Rosenberg et al., 2010;
Rosenberg et al., 2010; Wang et al., 2008). To assist further
structural and functional analysis and mechanistic under-
standing of ABCG2, we refined the closed apo model of
ABCG2 based on the three-dimensional map determined in
this study. We found that the model, particularly the TMDs,
did not fit well to the map (Fig. 6a). We therefore refined the
model based on the experimental three-dimensional map. The
quality of fitting for the final model was significantly improved,
particularly in the TMD region (Fig. 6b). The ICL2 between
TM4 and TM5 is long enough to account for some densities
between the TMD and the NBD and makes contact with the
NBD. The identity and location of the TM -helices of one
ABCG2 monomer in a homodimeric complex are shown in
Fig. 6(c). Several residues (Thr402 in TM1 and Arg482 and
Pro485 in TM3) predicted to be in the TMD and previously
shown to be functionally important are also indicated in the
refined model (Fig. 6c).
4. Discussion
In the present study, we report the first three-dimensional
structure of ABCG2 determined in the absence of nucleotides
and transported substrates to a resolution of 2.0 nm in the
vertical and in-plane directions. In this state, the homodimeric
complex of ABCG2 displays an inward-facing conformation,
with the NBDs widely separated from each other and the
drug-transport pathway formed by the TMDs (Fig. 5a). The
ABCG2 map best matched the murine ABCB1 structure
(PDB entry 4ksb), followed by the ABCB10 structure (closed
apo; PDB entry 3zdq), the murine ABCB1 structure (closed
apo; PDB entry 3g60) and the MsbA structure (open apo;
PDB entry 3b5w), but did not match the Sav1866 structure
(outward-facing; PDB entry 2hyd). It is worth noting that
apart from the Sav1866 structure, the other four structures
(PDB entries 4ksb, 3zdq, 3g60 and 3b5w) are all in an inward-
facing conformations but with a varying degree of separation
of the two NBDs. Structural studies to date suggest that when
ABC transporters are not co-crystallized with nucleotides they
generally tend to be in an inward-facing state. However, the
degree of separation of the two NBDs may vary depending on
the crystallization conditions or reflecting a range of flexibility
that is critical for the binding and/or transport of diverse
substrates, as demonstrated for ABCB1 (Aller et al., 2009; Jin
et al., 2012; Ward et al., 2013). Likewise, three-dimensional
structures of ABCB10 have also been determined in several
inward-facing conformations in the absence and even the
presence of nucleotide analogues (Shintre et al., 2013). The
fitting of alternative models to the ABCG2 map suggests that
the conformational state of ABCG2 observed in this study is
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likely to be an inward-facing closed apo state. Our results
appear to support the ATP-switch model, in which an inward-
facing state is proposed to be the conformational state prior to
substrate binding and transport in the drug-transport cycle
(Linton & Higgins, 2007). In contrast, in the constant-contact
model, no matter whether a substrate is bound or transported
or not, the NBDs never lose contact (George & Jones, 2012).
However, this three-dimensional structure of ABCG2 may
also represent a conformation specific to crystallization
conditions. Therefore, to further understand the mechanism of
ABCG2, it is important in the future to calculate its three-
dimensional map in the presence of a transported substrate,
which we have shown to possess a narrower and more
symmetric conformation (Rosenberg et al., 2010).
The resolution of the three-dimensional structure of
ABCG2 is sufficient to identify the NBD and the TMD as well
as their organization in the
homodimer based upon fitting to
the ABCB1 structure (PDB entry
4ksb; Fig. 5). Two unique areas of
the density in the ABCG2 map,
namely the ‘beak’ regions, which
are indicated by the open arrows
pointing to the regions located
between the TMD and the NBD
(Fig. 5a), cannot be accounted for
by the fitted ABCB1 model (PDB
entry 4ksb). Such areas may
represent the ABCG2 domains
that are not present in ABCB1
and seem to help in making crys-
talline contacts. ABCG2 has a
linker region between the NBD
and the TMD of almost 100 resi-
dues before the first predicted TM
-helix of the TMD, which is at
around residue 390 (Wang et al.,
2008). Therefore, another possi-
bility is that the ‘beak’ regions
may be accounted for by part of
the relatively long linker region
that extends from the N-terminus
of the TMD to the C-terminus of
the NBD, as illustrated in
Supplementary Fig. S4. In addi-
tion, the putative NBDs in the
ABCG2 map do not fully match
the NBDs of the ABCG2 model
(Fig. 6b). This is likely to be
because residues 285–390 that are
part of the NBD and represent a
relatively long linker region were
not modelled owing to a lack of
appropriate templates and were
therefore missing in the NBDs of
the model (Supplementary Fig.
S4). Whether the ‘beak’ regions
and the unmatched regions in the
putative NBDs might be
explained by the linker region or
part of the NBD remains to be
determined.
Although the resolution of the
current map is not sufficient to
trace the path of the polypeptide
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Figure 6
Alignment of homology models to the ABCG2 map. (a) Fitting of the original closed apo inward-facing
model to the map. (b) Fitting of the refined inward-facing model to the map. (c) A closer look at the TMDs.
TM -helices in the refined model are labelled 1, 2, 3, 4, 5 and 6 for TM1, TM2, TM3, TM4, TM5 and TM6
of one ABCG2 monomer (blue), respectively. Residues Thr402 (T402), Arg482 (R482) and Pro485 (P485)
as well as the GXXXG motif are depicted near their locations in one ABCG2 monomer (blue). The three
residues are indicated in ball-and stick representation and the GXXXG motif in TM1 is shown in green.
chain, nor to identify TM helices, the map can nevertheless be
interpreted in terms of the experimental membrane topology
of ABCG2 that we determined previously (Rosenberg et al.,
2010; Wang et al., 2008). The experimental topology config-
uration would be close to the topology for the ABCB
subfamily and the bacterial exporters Sav1866 and MsbA, but
with a much shorter ICL (the first ICL1) connecting TM2 and
TM3. The length (40 residues) of the second ICL2 connecting
TM4 and TM5 of ABCG2 is only slightly shorter than those of
ABCB1, Sav1866 and MsbA (49–60 residues). Based on this
experimental topology and using the murine ABCB1 structure
with PDB code 3g60 as a template, we developed an inward-
facing closed apo model of ABCG2 (Rosenberg et al., 2010).
The new experimental structural evidence has allowed the
refinement of the closed apo model (Fig. 6b). In the refined
model, the TM4–ICL2–TM5 region crosses over to directly
contact the NBD of an opposing monomer. Notably, ICL2
contains one cytoplasmic -helix that is connected to the NBD
of the opposing monomer and is likely to function as the
coupling helix, analoguous to those in ABCB1, MsbA and
Sav1866. As in ABCB1, MsbA and Sav1866, TM4 and TM5 in
ABCG2 are closely packed parallel to each other. However,
unlike in ABCB1, MsbA and Sav1866, which have two long
ICLs each half transporter molecule (ABCB1 and MsbA) or
each transporter molecule (Sav1866), there is only one such
ICL (ICL2) in each ABCG2 molecule. The sequence align-
ment between ABCG2 and the two halves of ABCB1 illus-
trates this significant difference between the two ABC
transporters (Supplementary Fig. S5). According to the
refined model, the dimensions of the area of the TM4–ICL2–
TM5 cross-over region of one monomer that directly contacts
the NBD of the opposing monomer are approximately 1.5 
4 nm. These unique features of the coupling helices might
imply a different mechanism of coupling of ATP binding/
hydrolysis to drug transport for ABCG2 versus other ABC
transporters. The resolution of the current ABCG2 map is not
sufficient to resolve molecular details of the NBD–TMD
interface; thus, exactly how ICL2 interacts with the NBD is
still not clear.
The refined model of ABCG2 provides novel insights into
the biochemical data, which are otherwise difficult to inter-
pret. Numerous studies have shown that mutations of Arg482
in TM3 significantly alter the substrate specificity of ABCG2
(Honjo et al., 2001; Miwa et al., 2003; O¨zvegy-Laczka et al.,
2005). In addition, our recent mutagenesis studies indicate
that Pro485 in TM3, which is just three residues apart from
Arg482, is also an important determinant of the substrate
specificity of ABCG2 (Ni et al., 2011). The reasons why
Arg482 and Pro485 are crucial for the substrate specificity of
ABCG2 are not known. We have proposed that Pro485 can
introduce a structurally flexible hinge in TM3, and Arg482 in
such a close position to Pro485 (Fig. 6c) is actually part of the
molecular hinge introduced by Pro485. According to the
refined model, TM3 is a rather short TM -helix connecting
the TM4–ICL2–TM5 region, and TM3 also contacts the
neighbouring TM1, TM2 and TM6 of the same ABCG2
monomer to form the drug-transport pathway (Fig. 6).
Therefore, any significant conformational changes induced by
the hinge in TM3 (through Pro485 and/or Arg482) would be
expected to affect drug binding by directly changing the
structure of the drug-binding cavity and/or the coupling
between ATP binding/hydrolysis and drug transport by
changing the configuration of TM4–ICL2–TM5 and hence the
interaction with the NBDs. The degree of conformational
change induced by the hinge may be dependent on the
physical or chemical nature of the drug molecules, such as size
or charge. Mutating Arg482 or Pro485 would affect or elim-
inate helical distortion of TM3 and helical packing with
neighbouring TMs as well as the configuration of TM4–ICL2–
TM5, therefore affecting drug binding and/or coupling with
ATP hydrolysis for some substrates.
We and others have shown that mutations of Thr402 in TM1
cause a general reduction in the efflux activity of ABCG2 (Ni,
Bikadi, Cai et al., 2010; Polgar et al., 2010). The refined model
of ABCG2 shows that Thr402 is located in TM1 but outside
the drug-transport pathway (Fig. 6c), suggesting that Thr402 is
not directly involved in interactions with drugs. On the other
hand, Thr402 can make interactions with residues in TM2 and
TM3 of the same ABCG2 monomer and thus play an impor-
tant role in stabilizing helical packing in ABCG2. Therefore,
mutations of Thr402 would destabilize the drug-transport
pathway and hence reduce the transport activity of ABCG2.
This finding is consistent with the location of Thr402 adjacent
to the GXXXG helical dimerization motif in TM1 (see Fig. 6c;
Polgar et al., 2010).
In summary, the first three-dimensional structure of human
ABCG2 determined in this study provides a molecular model
that is consistent with the biochemical data on this transporter,
with the results justifying the presence of a noncrystallo-
graphic twofold axis perpendicular to the two-dimensional
crystal plane. The map is consistent with a model-building
exercise in which ABCG2 in the absence of nucleotides and
transported substrates might be in an inward-facing confor-
mation. The structural data enhance our understanding of the
structure, function and mechanism of ABCG2 and can be used
to guide future structural and functional analysis of this
transporter. Since we have shown that ABCG2 undergoes
significant conformational changes upon drug binding
(Rosenberg et al., 2010), the next step in our study is to
calculate its three-dimensional map in the presence of a
transported drug molecule.
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